Geneva, Switzerland, 21 March 2012 – Addex Pharmaceuticals (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has changed its name to Addex Therapeutics. The name change reflects more closely the company’s focus on oral small molecule-based therapeutics. Addex’s ticker symbol on the Swiss Stock Exchange remains unchanged at ADXN.
Alongside the name change, Addex has revealed a new logo and website. The icon in the logo represents two things: the letter “X” from the Addex name and a receptor bound by a natural ligand or cell signaling molecule in the active site, depicted in blue, and an allosteric modulator bound to an allosteric site, in orange.
Addex has also introduced a new tag line: “expanding the realm of possible…” which is literally what the allosteric approach is doing for drug discovery. When applied to drug discovery, allostery offers the unique possibility of developing oral small molecule drugs for targets that were previously considered “undruggable” with conventional drug discovery approaches. Addex technology, therefore, expands the realm of druggable targets.
The new website provides information on the company’s strategy, pipeline and the allosteric modulation-based drug discovery and development technology platform. The new website also provides helpful information on the stock, corporate governance and corporate calendar featuring the company’s investor, media and scientific outreach activities.
This name change is subject to shareholder approval.
Addex Therapeutics (www.addextherapeutics.com) discovers and develops an emerging class of small molecule drugs, called allosteric modulators, which have the potential to be more specific and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs. The Company uses its proprietary discovery platform to address receptors and other proteins that are recognized as attractive targets for modulation of important diseases with unmet medical needs. The Company’s two lead products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or is being developed by Addex to treat Parkinson’s disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals Inc. to treat schizophrenia. Addex also is advancing several preclinical programs including: GABA-BR PAM for pain, overactive bladder and other disorders; mGluR4 PAM for Parkinson’s, anxiety and other diseases; GLP1R PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer’s disease and depression; and FSHR/LHR NAM for sex hormone dependent tumors & reproductive system disorders. In addition, Addex has discovery programs to identify allosteric modulators of: receptor tyrosine kinase superfamily, including TrkB PAM for treating neurodegenerative diseases (e.g. Alzheimer’s, Parkinson’s and Huntington’s diseases); and TNF receptor superfamily, including TNFR1 NAM for inflammation (e.g. rheumatoid arthritis) and other diseases.
Business Development & Communication
+41 22 884 15 11